The pharmacology of the cannabinoids is characterized by at least two very provocative phenomena. First, the multiplicity of effects. As I have mentioned throughout this review, most of these effects are due to actions on the central nervous system. The major problem in the search for a therapeutic agent in this series has been due to the inability to find a cannabinoid with the therapeutic action at doses below those that produce side effects. The high lipid solubility of the cannabinoids allows them to be distributed throughout the brain at reasonable doses. The second aspect of their pharmacology worthy of special mention is their low toxicity. Throughout this review, I have indicated that the minimal effective dose of delta 9-THC for a particular pharmacological effect in animals was higher than that usually consumed by man. Yet, in almost all cases, it was much lower than the dose which produced toxic effects in the same species. These two characteristics of the animal pharmacology of cannabinoids carry over to humans. For instance, each of the cannabinoids tested in man causes many side effects at active doses and lethal effects of overdose by humans are nonexistent or rare. Toxicity following chronic use may be a different issue. A great deal of work has been carried out in an attempt to characterize the pharmacological effects of cannabinoids. It is clear from the material reviewed in this article that most if not all of the predominant effects of cannabinoids in whole animals are due to the direct effects of these compounds on the central nervous system. Our state of knowledge is too limited to rule out the possibility that they also produce effects on certain peripheral organs. It is expected that the majority of these effects will be shown to be due to the interaction of the cannabinoids with the neuronal innervation of the organ rather than directly with the organ tissue itself. Very high doses of cannabinoids just like all active drugs have an effect on many organ systems. These are toxicologic not pharmacologic and are nonspecific. The effects of cannabinoids at the molecular level have been reviewed by Martin (182a) in this series. This type of research is expected to elucidate the mechanism of action of cannabinoids at the cellular level. It is clear that the cannabinoids produce a unique behavioral syndrome in laboratory animals and in man.(ABSTRACT TRUNCATED AT 400 WORDS)
大麻素的药理学具有至少两种非常引人关注的现象。其一,作用的多样性。正如我在这篇综述中一直提到的,这些作用大多归因于对中枢神经系统的作用。在寻找该系列治疗药物时的主要问题在于,无法找到一种在产生副作用剂量以下具有治疗作用的大麻素。大麻素的高脂溶性使其能够以合理剂量分布于整个大脑。其药理学值得特别提及的第二个方面是它们的低毒性。在这篇综述中我一直指出,动物中特定药理效应的δ9 - 四氢大麻酚最小有效剂量高于人类通常摄入的剂量。然而,在几乎所有情况下,它都远低于在同一物种中产生毒性作用的剂量。大麻素在动物药理学上的这两个特征同样适用于人类。例如,在人体中测试的每种大麻素在有效剂量下都会引起许多副作用,而且人类过量服用导致致死的情况不存在或很少见。长期使用后的毒性可能是另一个问题。为了描述大麻素的药理作用,已经开展了大量工作。从本文所综述的资料来看很明显,大麻素在整个动物体内的大多数(如果不是全部)主要作用是由于这些化合物对中枢神经系统的直接作用。我们的知识水平有限,无法排除它们也对某些外周器官产生作用的可能性。预计这些作用中的大多数将被证明是由于大麻素与器官的神经支配相互作用,而非直接与器官组织本身相互作用。与所有活性药物一样,非常高剂量的大麻素会对许多器官系统产生影响。这些是毒理学而非药理学的影响,并且是非特异性的。马丁(182a)在本系列中对大麻素在分子水平的作用进行了综述。这类研究有望阐明大麻素在细胞水平的作用机制。很明显,大麻素在实验动物和人类中会产生独特的行为综合征。(摘要截选至400字)